Hypoxanthine

Hypoxanthine

SCHEMBL472854

NC(=O)c1cccnc1.O=c1[nH]cnc2nc[nH]c12

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F7 P08709 1/20 0.61
F3 P13726 1/20 0.61
SARM1 Q6SZW1 1/20 0.61
SIRT2 Q8IXJ6 1/20 0.61
SIRT6 Q8N6T7 1/20 0.61
SIRT1 Q96EB6 1/20 0.61
SIRT3 Q9NTG7 1/20 0.61
SIRT5 Q9NXA8 1/20 0.61
SIRT4 Q9Y6E7 1/20 0.61
ALDH1A1 P00352 3/20 0.50
MKNK1 Q9BUB5 3/20 0.47
MKNK2 Q9HBH9 2/20 0.47
CYP3A4 P08684 2/20 0.45
APP P05067 1/20 0.42
GAA P10253 1/20 0.42
HCAR3 P49019 1/20 0.42
HCAR2 Q8TDS4 1/20 0.42
PIM1 P11309 1/20 0.41
NEK2 P51955 2/20 0.41
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hypoxanthine SCHEMBL9150757 0.91 SIRT2 (0.50) F7F3SARM1SIRT2SIRT6
Hypoxanthine SCHEMBL4083911 0.88 ALDH1A1 (0.49) F7F3SARM1SIRT2SIRT6
Mercaptopurine Anhydrous SCHEMBL6558420 0.86 F7 (0.58) F7F3SARM1SIRT2SIRT6
Guanine SCHEMBL1266684 0.86 PNP (0.60) F7F3SARM1SIRT2SIRT6
Hypoxanthine SCHEMBL1614959 0.86 ALDH1A1 (0.50) F7F3SARM1SIRT2SIRT6
Niacinamide SCHEMBL6558759 0.85 F7 (0.50) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL15700 0.84 PI4KA (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL22748487 0.84 PI4KA (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL2564210 0.84 PI4KA (0.55) F7F3SARM1SIRT2SIRT6
Adenine SCHEMBL23531102 0.83 PI4KA (0.54) F7F3SARM1SIRT2SIRT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF DISARM THERAPEUTICS, INC. 2024-07-18 US claimed
WO-2023077166-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION MATTERWORKS INC (US) 2023-05-04 WO claimed
US-20230137741-A1 METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION MATTERWORKS INC 2023-05-04 US claimed
US-20200129493-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF WASHINGTON UNIVERSITY (US) 2020-04-30 US claimed
CN-110545804-A SARM1 NAD enzyme activity inhibitor and application thereof UNIV WASHINGTON 2019-12-06 CN claimed
EP-3515426-A1 INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF Washington University (US) 2019-07-31 EP claimed
WO-2018057989-A1 INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF WASHINGTON UNIVERSITY (US) 2018-03-29 WO claimed
WO-2017114796-A1 ADENOSYLHOMOCYSTEINASE BINDING SUBSTANCES FOR MEDICAL USE LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2017-07-06 WO claimed
EP-3187180-A1 ADENOSYLHOMOCYSTEINASE BINDING SUBSTANCES FOR MEDICAL USE Ludwig-Maximilians-Universität München (DE) 2017-07-05 EP claimed
EP-2062979-B1 Method for measuring phosphoric acid NITTO BOSEKI CO LTD (JP) 2015-11-11 EP claimed
EP-0639646-A1 HIGH PRECISION DETERMINATION OF D-GLUCOSE-6-PHOSPHATE AND COMPOSITION THEREFOR ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1995-02-22 EP claimed
EP-0632133-A1 HIGHLY SENSITIVE DETERMINATION OF D-3-HYDROXYBUTYRIC ACID OR ACETOACETIC ACID AND COMPOSITION THEREFOR Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1995-01-04 EP claimed
EP-0351774-B1 Determination of blood ammonia levels ABBOTT LAB (US) 1994-09-28 EP claimed
US-5286627-A Reacting with a steroid dehydrogenase; NAPD or NAD as a coenzyme ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1994-02-15 US claimed
US-5266463-A Highly sensitive assay method for L-carnitine and composition for practicing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1993-11-30 US claimed
US-5141853-A Glutamate dehydrogenase, alpha-ketoglutarate and nicrotinamide hypoxanthine dinucleotide phosphate ABBOTT LABORATORIES (US) 1992-08-25 US claimed
EP-0477001-A2 Highly sensitive assay method for myo-inositol and composition for practicing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1992-03-25 EP claimed
EP-0437373-A1 High sensitive assay method of L-carnitine and composition for an assay ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1991-07-17 EP claimed
EP-0393624-A2 Method of high-sensitive analysis of bile acid and reagent composition for the analysis ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1990-10-24 EP claimed
EP-0351774-A2 Determination of blood ammonia levels ABBOTT LABORATORIES (US) 1990-01-24 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200129493-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF SARM1, NADK, NNMT F7 4801/4885F3 4145/4885SARM1 1/4885
US-20240238264-A1 INHIBITORS OF SARM1 NADASE ACTIVITY AND USES THEREOF SARM1, NADK, NNMT F7 4801/4885F3 4145/4885SARM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.